Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care 14 May 2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians 07 May 2019
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off 09 April 2019
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre 03 April 2019
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW 11 March 2019
Novartis receives European Commission approval for self-administration of Xolair® across all indications 13 December 2018
Novartis rises to second place in 2018 Access to Medicine Index 22 November 2018
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH 29 October 2018
Alcon to develop SMART Suite digital health platform for cataract surgery 23 October 2018
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access 12 October 2018
Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges 05 October 2018
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis 11 September 2018
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) 27 August 2018
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation 23 August 2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention 30 July 2018
Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month 03 July 2018
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin 26 June 2018
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine 04 June 2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® 28 May 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer 21 May 2018
Build the future of health through collaboration & innovation